Survodutide posts 16.6% weight loss in first Phase 3 readout for a dual GLP-1/glucagon drug

Survodutide reported a mean 16.6% weight loss at 76 weeks in the Phase 3 SYNCHRONIZE-1 trial, against 3.2% for placebo, according to a 2026 obesity drug pipeline calendar ^[1]. The same calendar describes the result as the first Phase 3 topline for a dual GLP-1/glucagon agonist, and notes that it came in lower than the retatrutide and CagriSema benchmarks ^[1].

Survodutide is an investigational drug designed to act on two hormone receptors, GLP-1 and glucagon, rather than on GLP-1 alone ^[1]. That makes it a different mechanism from semaglutide (Ozempic, Wegovy and Rybelsus), which acts on the GLP-1 receptor, and from tirzepatide (Mounjaro and Zepbound). The glucagon component is the part of the design that has drawn interest for its potential effect on the liver, though liver-fat or liver-disease outcomes from SYNCHRONIZE-1 have not been reported.

The 16.6% figure sits below the highest weight-loss numbers reported so far for other drugs still in development ^[1]. That comparison comes with limits: the trials differ in length, in the patients enrolled and in how the results are counted, so the percentages are not a like-for-like ranking of effectiveness. What the calendar does show is that survodutide's first Phase 3 result lands in the middle of a crowded field rather than at the front of it ^[1].

Several things about SYNCHRONIZE-1 have not been reported. Adverse-event rates, the share of participants who stopped treatment, how weight loss was distributed across the trial population, and whether the liver-related measures differed from placebo are not in the topline. Nor has a regulatory filing been disclosed, so there is no approval timeline to point to. The drug is not approved for any use in the United States.

The calendar also tracks the rest of the field. CagriSema, a GLP-1 plus amylin combination, remains the main regulatory item for 2026, with FDA review expected through late 2026; the FDA has not publicly confirmed a decision date ^[1]. Survodutide's SYNCHRONIZE-1 data are listed among the presentations at ADA 2026, scheduled for June 5–8 in New Orleans, where fuller analyses are typically shown ^[1].

Why it matters for patients

For anyone taking semaglutide (Ozempic, Wegovy or Rybelsus) or tirzepatide (Mounjaro or Zepbound) today, this readout changes nothing about their prescription, their dose or their insurance coverage. No new drug is available as a result of it.

What the number does show is the range of outcomes the next wave of obesity drugs is producing. A 16.6% average weight loss over 76 weeks is a meaningful reduction, and it is also below the top results reported for other investigational drugs ^[1]. Patients who are waiting for a larger-effect option, or for a drug that also targets liver fat, do not yet have the data to judge whether survodutide would be that option. Its liver-related results and its side-effect profile are still unknown.

It is also worth noting the timescale. Even if survodutide is eventually filed and approved, that process typically takes years, and no filing has been reported. Nothing in this readout shortens the wait.

What happens next

• ADA 2026 runs June 5–8 in New Orleans, with SYNCHRONIZE-1 listed among the presentations ^[1].
• CagriSema's FDA review is expected to run through late 2026, with no publicly confirmed decision date ^[1].
• Survodutide's manufacturer has not disclosed any regulatory submission, and no additional Phase 3 readout date for the drug has been reported ^[1].